Annexon (Nasdaq: ANNX) will present at the Bank of America Securities Health Care Conference on May 13, 2026 at 11:20 a.m. PT. Douglas Love, President and CEO, will deliver the presentation.
A live webcast is available via the company Investors page and a replay will be archived for 30 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ANNX
-0.35%
1 alert
-0.35%Session close to close
$897.04MMarket Cap
0.0xRel. Volume
In the May 6 session, ANNX declined 0.35%, reflecting a mild negative market reaction.
This announcement adds another investor conference appearance to Annexon’s ongoing outreach, followi...
Analysis
This announcement adds another investor conference appearance to Annexon’s ongoing outreach, following prior events in February and April 2026. The company enters the Bank of America conference with shares above the 200-day MA of $4.28 and a recent update citing $238.3 million in cash and short-term investments and a 2025 net loss of $208.5 million. Investors may monitor progress of late-stage programs, capital-raising flexibility from share authorization proposals, and upcoming ARCHER II Phase 3 milestones.
Key Figures
Cash & short-term investments:$238.3 millionNet loss:$208.5 millionR&D expenses:$184.7 million+5 more
8 metrics
Cash & short-term investments$238.3 millionAs of December 31, 2025
Net loss$208.5 millionFull-year 2025 net loss
R&D expenses$184.7 millionResearch and development expenses for 2025
G&A expenses$31.7 millionGeneral and administrative expenses for 2025
EPS$1.34 loss per share2025 net loss attributable to common stockholders
Authorized common stock300,000,000 sharesCurrent authorized common shares per proxy
Proposed authorized shares500,000,000 sharesProposed increase in authorized common stock
Shares outstanding162,507,278 sharesOutstanding as of April 13, 2026
KOL event on vonaprument and ARCHER II Phase 3 trial in GA.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent company events, including conferences and pipeline/financial updates, have generally seen modestly positive price reactions, with no instances of strong negative divergence.
Recent Company History
Over the last few months, Annexon has combined routine investor outreach with substantial pipeline and financing disclosures. The March 30, 2026 earnings and pipeline update highlighted late-stage programs and a cash position of $238.3 million, which preceded a 11.69% gain. Multiple conference presentations on February 24 and April 8, 2026 produced small positive moves. A KOL event announcement on February 17, 2026 around vonaprument and the ARCHER II trial also saw a constructive price reaction. Today’s Bank of America conference appearance fits this pattern of ongoing investor communication.
"Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform"
A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.
immunotherapiesmedical
"next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
neuroinflammatorymedical
"targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people"
Neuroinflammatory describes inflammation occurring in the brain, spinal cord or peripheral nerves when the body's immune response becomes active in nervous tissue. For investors, it matters because neuroinflammatory processes are central to many neurological diseases and can drive demand for new drugs, affect clinical trial outcomes, and influence regulatory decisions—similar to how a neighborhood dispute can change local services and property values, inflammation can reshape treatment needs and company prospects.
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., President and Chief Executive Officer, will present at the Bank of America Securities Health Care Conference 2026 on Wednesday, May 13, 2026 at 11:20 a.m. PT.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to millions of patients to help them live their best lives. To learn more visit annexonbio.com.
When will Annexon (ANNX) present at the Bank of America Health Care Conference?
Annexon will present on Wednesday, May 13, 2026 at 11:20 a.m. PT. According to Annexon, Douglas Love, President and CEO, is scheduled to deliver the company presentation at that time during the conference.
How can I watch Annexon (ANNX) live at the May 13, 2026 presentation?
You can watch the live webcast via the company Investors page under Events & Presentations. According to Annexon, the webcast link is available on www.annexonbio.com for live viewing.
Will Annexon (ANNX) make the presentation replay available after the May 13, 2026 event?
Yes. A replay will be archived on the company website for 30 days following the presentation. According to Annexon, the replay will remain accessible in the Events & Presentations section.
Who will present for Annexon (ANNX) at the Bank of America Health Care Conference 2026?
Douglas Love, President and Chief Executive Officer, will present on behalf of Annexon. According to Annexon, he will represent the company and discuss its targeted immunotherapy platform aimed at neuroinflammatory diseases.
Where on Annexon's website can investors find the May 13, 2026 webcast for ANNX?
The webcast and replay are posted under the Events & Presentations section on the Investors page. According to Annexon, investors should visit www.annexonbio.com to access the webcast materials.
